Seven Post Investment Office’s iShares Core S&P Small-Cap ETF IJR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$934K Hold
6,298
0.27% 25
2026
Q1
$783K Hold
6,298
0.25% 24
2025
Q4
$757K Hold
6,298
0.27% 23
2025
Q3
$748K Hold
6,298
0.27% 23
2025
Q2
$688K Hold
6,298
0.26% 23
2025
Q1
$659K Hold
6,298
0.25% 22
2024
Q4
$726K Hold
6,298
0.28% 22
2024
Q3
$737K Hold
6,298
0.11% 31
2024
Q2
$672K Hold
6,298
0.12% 33
2024
Q1
$696K Hold
6,298
0.17% 33
2023
Q4
$682K Sell
6,298
-2,523
-29% -$243K 0.17% 33
2023
Q3
$832K Hold
8,821
0.23% 32
2023
Q2
$879K Hold
8,821
0.27% 29
2023
Q1
$853K Hold
8,821
0.31% 25
2022
Q4
$835K Hold
8,821
0.29% 26
2022
Q3
$769K Sell
8,821
-12,092
-58% -$1.17M 0.3% 23
2022
Q2
$1.93M Buy
+20,913
New +$2.08M 0.72% 16

Other funds holding IJR

Seven Post Investment Office's IJR Position: Q2 2026 in Review

Seven Post Investment Office held its iShares Core S&P Small-Cap ETF (IJR) position steady in Q2 2026 at 6,298 shares worth $934K. The position accounts for 0.27% of the portfolio, ranked #25.

Seven Post Investment Office first reported a position in IJR in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.93M in Q2 2022. 1,519 funds tracked by Wall St. Rank hold IJR as of Q2 2026.

  • Seven Post Investment Office held 6,298 shares of iShares Core S&P Small-Cap ETF worth $934K as of Q2 2026.
  • Seven Post Investment Office left its iShares Core S&P Small-Cap ETF share count unchanged in Q2 2026.
  • iShares Core S&P Small-Cap ETF made up 0.27% of Seven Post Investment Office's portfolio in Q2 2026, its #25 holding.
  • Seven Post Investment Office first reported a position in iShares Core S&P Small-Cap ETF in Q2 2022 and has held it in 17 quarters since.
  • Seven Post Investment Office's iShares Core S&P Small-Cap ETF position peaked at $1.93M in Q2 2022.
  • 1,519 funds tracked by Wall St. Rank held iShares Core S&P Small-Cap ETF as of Q2 2026.

Based on Seven Post Investment Office's 13F filing for Q2 2026, filed 28 Jul 2026.